Chapter 61. Glaucoma
The preferred treatment option for a 67-year-old man with primary open-angle glaucoma (POAG), no significant past medical history (PMH), and allergy to benzalkonium chloride is:
An appropriate counseling statements for timolol is:
A. This medication has no significant systemic effects.
B. This medication may cause mydriasis.
C. Do not use this medication if you are allergic to sulfonamides.
D. This medication may cause an increase in iris pigmentation.
E. This medication may cause bradycardia.
All of the following characteristics would increase a patient’s risk of developing primary angle-closure glaucoma except:
C. Shallow anterior chamber
D. Central corneal thickness of 560 μm
The following drug would be contraindicated in a patient with with primary open-angle glaucoma (POAG) and allergy to sulfonamides:
The following drug has little clinically significant systemic adverse effects:
The following drug may darken pigmentation of the iris:
The following medications are likely to increase IOP in a patient with primary angle-closure glaucoma (PACG) except: